Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study

References

• Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003;39:1990–2005.
   PubMed Web of Science ®Google Scholar
• Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol 2009;69:271–8.
   PubMed Web of Science ®Google Scholar
• Randen M, Rutqvist LE, Johansson H. Cancer patients without a known primary: Incidence and survival trends in Sweden 1960–2007. Acta Oncol 2009;48(48):915–20.
   PubMedGoogle Scholar
• Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: From autopsy to microarray. Eur J Cancer 2007;43:2026–36.
   PubMed Web of Science ®Google Scholar
• Fizazi K. Treatment of patients with specific subsets of carcinoma of an unknown primary site. Ann Oncol 2006;17(Suppl 10):x177–80.
   PubMedGoogle Scholar
• Pavlidis N. Forty years experience of treating cancer of unknown primary. Acta Oncol 2007;46:592–601.
   PubMed Web of Science ®Google Scholar
• Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004;22:3852–9.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, De MF, Rinaldi M, Crino L, Gridelli C, Ricci S, . Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285–91.
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92–8.
   PubMed Web of Science ®Google Scholar
• Burris HA, III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, . Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403–13.
   PubMed Web of Science ®Google Scholar
• Rivera F, Lopez-Tarruella S, Vega-Villegas ME, Salcedo M. Treatment of advanced pancreatic cancer: From gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev 2009;35:335–9.
   PubMed Web of Science ®Google Scholar
• Sorensen JB, Stenbygaard LE, Dombernowsky P, Hansen HH. Paclitaxel, gemcitabine, and cisplatin in nonresectable non-small-cell lung cancer. Ann Oncol 1999;10: 1043–9.
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16.
   PubMed Web of Science ®Google Scholar
• Gothelf A, Daugaard G, Nelausen K. Paclitaxel, cisplatin and gemcitabine in the treatment of unknown primary tumours, a phase II study. Ann Oncol 2002; 13 Suppl 5: abstract 88P.
   Google Scholar
• Palmeri S, Lorusso V, Palmeri L, Vaglica M, Porta C, Nortilli R, . Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site: Results of an Italian multicenter, randomized, phase II study. Cancer 2006;107:2898–905.
   PubMed Web of Science ®Google Scholar
• Balana C, Manzano JL, Moreno I, Cirauqui B, Abad A, Font A, . Phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site. Ann Oncol 2003;14:1425–9.
   PubMed Web of Science ®Google Scholar
• Berry W, Elkordy M, O'Rourke M, Khan M, Asmar L. Results of a phase II study of weekly paclitaxel plus carboplatin in advanced carcinoma of unknown primary origin: A reasonable regimen for the community-based clinic? Cancer Invest 2007;25:27–31.
   PubMed Web of Science ®Google Scholar
• Bouleuc C, Saghatchian M, Di Tullio L, Louvet C, Levy E, Di Palma M, . A multicenter phase II study of docetaxel and cisplatin in the treatment of cancer of unknown primary site (CUP). Proc Am Soc Clin 2001;20:abstact 2300.
   Google Scholar
• Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, . Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 2000;18:3101–7.
   PubMed Web of Science ®Google Scholar
• Culine S, Lortholary A, Voigt JJ, Bugat R, Theodore C, Priou F, . Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: Results of a randomized phase II study–trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 2003;21:3479–82.
   PubMed Web of Science ®Google Scholar
• El-Rayes BF, Shields AF, Zalupski M, Heilbrun LK, Jain V, Terry D, . A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary. Am J Clin Oncol 2005;28:152–6.
   PubMed Web of Science ®Google Scholar
• Greco FA, Burris HA, III, Erland JB, Gray JR, Kalman LA, Schreeder MT, . Carcinoma of unknown primary site. Cancer 2000;89:2655–60.
   PubMed Web of Science ®Google Scholar
• Greco FA, Erland JB, Morrissey LH, Burris HA, III, Hermann RC, Steis R, . Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 2000;11:211–5.
   PubMed Web of Science ®Google Scholar
• Greco FA, Burris HA, III, Litchy S, Barton JH, Bradof JE, Richards P, . Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: A Minnie Pearl Cancer Research Network study. J Clin Oncol 2002;20:1651–6.
   PubMed Web of Science ®Google Scholar
• Greco FA, Rodriguez GI, Shaffer DW, Hermann R, Litchy S, Yardley DA, . Carcinoma of unknown primary site: Sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: A Minnie Pearl Cancer Research Network phase II trial. Oncologist 2004;9:644–52.
   PubMed Web of Science ®Google Scholar
• Gross-Goupil M, Fourcade A, Blot F, Penel N, Negrier S, Culine S, . A randomized trial of cisplatin with or without gemcitabine in patients (pts) with carcinoma of an unknown primary (CUP) and without poor prognostic factors: Results of GEFCAPI 02. Ann Oncol 2008;19 Suppl 8: abstract 798P.
   Google Scholar
• Hainsworth JD, Erland JB, Kalman LA, Schreeder MT, Greco FA. Carcinoma of unknown primary site: Treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol 1997;15:2385–93.
   PubMed Web of Science ®Google Scholar
• Huebner G, Link H, Kohne CH, Stahl M, Kretzschmar A, Steinbach S, . Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer 2009;100:44–49.
   PubMed Web of Science ®Google Scholar
• Mel JPM, Balaña C, López-Vega J, Casado A, Segura A, Cervera J, . Phase II study of Docetaxel (D), Carboplatin (C) and Gemcitabine (G), in advanced tumors of unknown primary site. J Clin Oncol 2006;4 Suppl 18: abstract 12028.
   Google Scholar
• Park YH, Ryoo BY, Choi SJ, Yang SH, Kim HT. A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site. Jpn J Clin Oncol 2004;34:681–5.
   PubMed Web of Science ®Google Scholar
• Pentheroudakis G, Briasoulis E, Kalofonos HP, Fountzilas G, Economopoulos T, Samelis G, . Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group phase II study. Acta Oncol 2008;47:1148–55.
   PubMed Web of Science ®Google Scholar
• Pittman KB, Olver IN, Koczwara B, Kotasek D, Patterson WK, Keefe DM, . Gemcitabine and carboplatin in carcinoma of unknown primary site: A phase 2 Adelaide Cancer Trials and Education Collaborative study. Br J Cancer 2006;95: 1309–13.
   PubMed Web of Science ®Google Scholar
• Pouessel D, Culine S, Becht C, Ychou M, Romieu G, Fabbro M, . Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer 2004;100:1257–61.
   PubMed Web of Science ®Google Scholar
• Schneider BJ, El-Rayes B, Muler JH, Philip PA, Kalemkerian GP, Griffith KA, . Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site. Cancer 2007;110:770–5.
   PubMed Web of Science ®Google Scholar
• Pentheroudakis G, Greco FA, Pavlidis N. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: A systematic literature review. Cancer Treat Rev 2008;35:221–227.
   PubMed Web of Science ®Google Scholar
• Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, . Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002;20:4679–83.
   PubMed Web of Science ®Google Scholar
• Ponce LJ, Segura HA, Diaz BR, Gimenez OA, Aparisi AF, Fleitas KT, . Carcinoma of unknown primary site: Development in a single institution of a prognostic model based on clinical and serum variables. Clin Transl Oncol 2007;9:452–8.
   PubMed Web of Science ®Google Scholar
• Seve P, Ray-Coquard I, Trillet-Lenoir V, Sawyer M, Hanson J, Broussolle C, . Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer 2006;107:2698–705.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Spigel DR, Thompson DS, Murphy PB, Lane CM, Waterhouse DM, . Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. Oncologist 2009;14:1189–1197.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Spigel DR, Farley C, Thompson DS, Shipley DL, Greco FA. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: The Minnie Pearl Cancer Research Network. J Clin Oncol 2007;25: 1747–52.
   PubMed Web of Science ®Google Scholar
• Bridgewater J, van LR, Floore A, Van't VL. Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. Br J Cancer 2008;98:1425–30.
   PubMed Web of Science ®Google Scholar
• Horlings HM, van Laar RK, Kerst JM, Helgason HH, Wesseling J, van der Hoeven JJ, . Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol 2008;26: 4435–41.
   PubMed Web of Science ®Google Scholar
• Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, Jatkoe T, . Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 2008;26:4442–8.
   PubMed Web of Science ®Google Scholar